2-Amino-1,3,5(10)-estratriene

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 2-Amino-1,3,5(10)-estratriene
• 英文别名: 2-Amino-Δ^1.3.5(10)-oestratrien；(8S,9S,13S,14S)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-2-amine
• 化学式: C₁₈H₂₅N
• 分子量: 255.403
• InChiKey: NXDMMURHUGXWPU-MVJTYMMSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  19
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-Amino-1,3,5(10)-estratriene 生成 2-Hydroxy-Δ^1,3,5(10)-oestratrien
  参考文献：
  名称：

  Dannenberg,H.; Koehler,T., Chemische Berichte, 1964, vol. 97, p. 140 - 150

  摘要：

  DOI：
• 作为产物：
  描述：

  雌酚酮 生成 2-Amino-1,3,5(10)-estratriene
  参考文献：
  名称：

  Inhibitors of type 5 and type 3 17&bgr;-hydroxysteroid dehydrogenase and methods for their use

  摘要：

  揭示了针对对雄激素或雌激素活性敏感的疾病的医疗治疗和/或抑制疾病发展的新方法。这些治疗方法利用了5型和/或3型17β-羟基类固醇脱氢酶的抑制剂。还披露了新型的5型17β-羟基类固醇脱氢酶抑制剂，以及新型的3型17β-羟基类固醇脱氢酶抑制剂。

  公开号：

  US06541463B1

文献信息

• Inhibitors of type 5 and type 3 17beta-hydroxysteroid dehydrogenase and methods for their use
  申请人：Endorecherche, Inc.

  公开号：US20040082556A1

  公开（公告）日：2004-04-29

  Novel methods of medical treatment and/or inhibition of development of diseases are disclosed for diseases that are sensitive to androgenic or estrogenic activity. The treatments utilize inhibitors of type 5 and/or type 3 17&bgr;-hydroxysteroid dehydrogenase. Novel inhibitors of type 5 17&bgr;-hydroxysteroid dehydrogenase are also disclosed, as are novel inhibitors of type 3 17&bgr;-hydroxysteroid dehydrogenase.

  本发明揭示了一种针对对雄激素或雌激素活性敏感的疾病的新型医疗治疗和/或抑制疾病发展的方法。这些治疗方法利用了类型5和/或类型3的17β-羟基类固醇脱氢酶的抑制剂。本发明还揭示了新型的类型5 17β-羟基类固醇脱氢酶抑制剂，以及新型的类型3 17β-羟基类固醇脱氢酶抑制剂。
• Antiangiogenic agents
  申请人：Agoston E. Gregory

  公开号：US20050192258A1

  公开（公告）日：2005-09-01

  Compositions and methods for treating mammalian disease characterized by undesirable angiogenesis by administering derivatives of 2-methoxyestradiol of the general formula: wherein the variables are defined in the specification.

  通过给予2-甲氧基雌二醇衍生物治疗哺乳动物疾病的组合物和方法，该疾病的特征是不良血管生成，其中衍生物的一般公式为：其中变量在规范中定义。
• Inhibitors of type 5 and 3 17beta-hydroxysteroid dehydrogenase and methods for their use
  申请人：Endorecherche Inc.

  公开号：EP1321146A2

  公开（公告）日：2003-06-25

  Novel methods of medical treatment and/or inhibition of development of diseases are disclosed for diseases that are sensitive to androgenic or estrogenic activity. The treatments utilize inhibitors of type 5 and/or type 3 17β-hydroxysteroid dehydrogenase. Novel inhibitors of type 5 17β-hydroxysteroid dehydrogenase are also disclosed, as are novel inhibitors of type 3 17β-hydroxysteroid dehydrogenase.

  针对对雄激素或雌激素活性敏感的疾病，公开了新的医疗和/或抑制疾病发展的方法。这些治疗方法利用了 5 型和/或 3 型 17β- 羟类固醇脱氢酶的抑制剂。还公开了 5 型 17β- 羟类固醇脱氢酶的新型抑制剂，以及 3 型 17β- 羟类固醇脱氢酶的新型抑制剂。
• US6541463B1
  申请人：——

  公开号：US6541463B1

  公开（公告）日：2003-04-01
• Inhibitors of type 5 and type 3 17&bgr;-hydroxysteroid dehydrogenase and methods for their use
  申请人：Endorecherche, Inc.

  公开号：US06541463B1

  公开（公告）日：2003-04-01

  Novel methods of medical treatment and/or inhibition of development of diseases are disclosed for diseases that are sensitive to androgenic or estrogenic activity. The treatments utilize inhibitors of type 5 and/or type 3 17&bgr;-hydroxysteroid dehydrogenase. Novel inhibitors of type 5 17&bgr;-hydroxysteroid dehydrogenase are also disclosed, as are novel inhibitors of type 3 17&bgr;-hydroxysteroid dehydrogenase.

  揭示了针对对雄激素或雌激素活性敏感的疾病的医疗治疗和/或抑制疾病发展的新方法。这些治疗方法利用了5型和/或3型17β-羟基类固醇脱氢酶的抑制剂。还披露了新型的5型17β-羟基类固醇脱氢酶抑制剂，以及新型的3型17β-羟基类固醇脱氢酶抑制剂。